THE ANGIOTENSIN-II TYPE-1 RECEPTOR ANTAGONISTS - A NEW CLASS OF ANTIHYPERTENSIVE DRUGS

被引：111

作者：

BAUER, JH ^{[1
]}

REAMS, GP ^{[1
]}

机构：

[1] HARRY S TRUMAN MEM VET HOSP, MED SERV, COLUMBIA, MO 65201 USA

来源：

ARCHIVES OF INTERNAL MEDICINE | 1995年 / 155卷 / 13期

关键词：

D O I：

10.1001/archinte.155.13.1361

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

he angiotensin II (AII) type 1 receptor antagonists represent a new pharmacologic class of drugs that are specifically designed to displace AII from its type 1 receptor subtype. These drugs antagonize AII-induced biologic actions, including smooth-muscle contraction, sympathetic presser mechanisms, and aldosterone release. Initial clinical trials suggest that these drugs are effective in the treatment of essential hypertension and hypertensive patients with intrinsic renal disease. Thus, they are the newest addition to the therapeutic armamentarium for the treatment of hypertensive diseases. We review the developmental history and pharmacology of the AII type 1 receptor antagonists. We specifically discuss the following factors: mechanism(s) of action; members under clinical investigation; effects on renal function, salt and water excretion, and plasma renin activity, plasma AII type 1, and plasma aldosterone concentrations; and efficacy and safety. Given the demonstrable benefits of AII type 1 receptor blockade, these drugs should achieve broad utility in the treatment of hypertensive diseases.

引用

页码：1361 / 1368

页数：8

共 90 条

[31] HYPERTENSIVE MECHANISMS AND CONVERTING ENZYME-INHIBITORS [J].

FERRARIO, CM ;

JAISWAL, N ;

YAMAMOTO, K ;

DIZ, DI ;

SCHIAVONE, MT .

CLINICAL CARDIOLOGY, 1991, 14 (08) :56-62

[32] NEW THERAPEUTIC AGENTS IN THE MANAGEMENT OF HYPERTENSION - ANGIOTENSIN II-RECEPTOR ANTAGONISTS AND RENIN INHIBITORS [J].

FOOTE, EF ;

HALSTENSON, CE .

ANNALS OF PHARMACOTHERAPY, 1993, 27 (12) :1495-1503

[33]

FURUKAWA Y, 1982, Patent No. 4355040

[34] THE ANTIPROTEINURIC EFFECT OF ACE-INHIBITION MEDIATED BY INTERFERENCE IN THE RENIN-ANGIOTENSIN SYSTEM [J].

GANSEVOORT, RT ;

DEZEEUW, D ;

DEJONG, PE .

KIDNEY INTERNATIONAL, 1994, 45 (03) :861-867

[35]

GANSEVOORT RT, 1994, J HYPERTENS, V12, pS37

[36] EFFECTS OF LOSARTAN ON BLOOD-PRESSURE, PLASMA-RENIN ACTIVITY, AND ANGIOTENSIN-II IN VOLUNTEERS [J].

GOLDBERG, MR ;

TANAKA, W ;

BARCHOWSKY, A ;

BRADSTREET, TE ;

MCCREA, J ;

LO, MW ;

MCWILLIAMS, EJ ;

BJORNSSON, TD .

HYPERTENSION, 1993, 21 (05) :704-713

[37] BIOCHEMICAL EFFECTS OF LOSARTAN, A NONPEPTIDE ANGIOTENSIN-II RECEPTOR ANTAGONIST, ON THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN HYPERTENSIVE PATIENTS [J].

GOLDBERG, MR ;

BRADSTREET, TE ;

MCWILLIAMS, EJ ;

TANAKA, WK ;

LIPERT, S ;

BJORNSSON, TD ;

WALDMAN, SA ;

OSBORNE, B ;

PIVADORI, L ;

LEWIS, G ;

BLUM, R ;

HERMAN, T ;

ABRAHAM, PA ;

HALSTENSON, CN ;

LO, MW ;

LU, H ;

SPECTOR, R .

HYPERTENSION, 1995, 25 (01) :37-46

[38] MOLECULAR-BIOLOGY OF THE RENIN-ANGIOTENSIN SYSTEM [J].

GRIENDLING, KK ;

MURPHY, TJ ;

ALEXANDER, RW .

CIRCULATION, 1993, 87 (06) :1816-1828

[39] VASODILATOR THERAPY FOR CONGESTIVE-HEART-FAILURE - LESSONS FROM MORTALITY TRIALS [J].

GRODEN, DL .

ARCHIVES OF INTERNAL MEDICINE, 1993, 153 (04) :445-454

[40] HEMODYNAMIC AND HUMORAL EFFECTS OF THE ANGIOTENSIN-II ANTAGONIST LOSARTAN IN ESSENTIAL-HYPERTENSION [J].

GROSSMAN, E ;

PELEG, E ;

CARROLL, J ;

SHAMISS, A ;

ROSENTHAL, T .

AMERICAN JOURNAL OF HYPERTENSION, 1994, 7 (12) :1041-1044

← 1 2 3 4 5 6 7 8 9 →